



Orexigen Therapeutics, Inc.  
3344 North Torrey Pines Court  
Suite 200  
La Jolla, CA 92037  
Phone: 858-875-8600  
Fax 858-875-8650

[www.orexigen.com](http://www.orexigen.com)

May 14, 2018

**Contrave® remains available for your appropriate patients struggling to lose weight.**

Dear Health Care Provider:

In an effort to keep you updated on the acquisition of Orexigen Therapeutics and Contrave® (naltrexone HCl and bupropion HCl extended release), on April 23, 2018 Orexigen Therapeutics announced that it has entered into an agreement to sell substantially all of the assets of the company to an initial bidder. The deal is subject to higher and better offers.

**This process and the outcome will not affect your ability to prescribe CONTRAVE or for your patients to start and stay on CONTRAVE.** We have taken steps to ensure supply during this process. In fact, CONTRAVE has patent protection through 2030. CONTRAVE continues to be the #1 prescribed branded weight loss medicine and continues to grow compared to last year. Thank you for continuing to prescribe CONTRAVE for your patients.

Many of you have requested resources to let your patients know that you offer CONTRAVE as an option within your practice and support material to educate patients on dosing, helpful hints on diet and exercise and adherence to therapy. Please click <https://contravehcp.com/resource-portal/> to review these resources. We also have many resources to support patients in reaching their weight loss goals (<https://contrave.com/health-and-fitness>)

As a reminder, CONTRAVE is a prescription weight-loss medicine that may help some adults with a body mass index (BMI) of 30 kg/m<sup>2</sup> or greater (obese), or adults with a BMI of 27 kg/m<sup>2</sup> or greater (overweight) with at least one weight-related medical problem such as high blood pressure, high cholesterol, or type 2 diabetes, lose weight and keep the weight off.

One of the ingredients in CONTRAVE, bupropion, may increase the risk of suicidal thinking in children, adolescents, and young adults. CONTRAVE patients should be monitored for suicidal thoughts and behaviors. In patients taking bupropion for smoking cessation, serious neuropsychiatric adverse events have been reported. CONTRAVE is not approved for use in children under the age of 18.

Click [here](#) for our full prescribing information including important safety information.

If you have any questions please contact your local Representative, Health Science Associate or the Orexigen Call Center at 1 (844) 551-2927.

Thank you for all you have done to support Orexigen and Contrave® up until now and thank you in advance for your ongoing support as we transition through this process.

Very truly yours,

Michael Narachi  
President & Chief Executive Officer

1. Source: IQVIA NPA data Sept 2014 through Jan 2018 and the IQVIA Persistence and Adherence study conducted June 2016